News

Chinese researchers reveal that low-level red light therapy may control myopia in children but raises concerns about retinal damage and cone density reduction.

Patricia Buehler, MD, MPH, presented a poster and two patient films at the ASCRS annual meeting, focused on minimally-invasive blepharoplasty device Ziplyft (Osheru).

AI’s use in diagnostic tools, surgical guidance, and its ethical considerations in ophthalmology are transforming the field

A study reports minimal rotation and improved near vision following implantation of the Eyhance toric lens.

Sheng Lim, MD, FRCOphth, discussed the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP.

Data show excellent refractive stability, strong visual acuity across all distances, and contrast sensitivity comparable to monofocal IOLs.

Alex Hacopian, MD, speaks about patient-reported outcomes from a presbyopia-correcting IOL at the 2025 ASCRS annual meeting.

Allotex launches its innovative eye implant for near vision restoration, appointing Michael Mrochen as CEO to drive global expansion and market access.

George O. Waring IV, MD, FACS, discusses the “vision for a lifetime” approach and how modern advancements allow tailored treatments for every stage of eye maturity.

Scientists enhance eye imaging with AI, achieving high-resolution views of retinal cells, potentially revolutionizing disease detection and monitoring in clinics.

Researchers unveil a groundbreaking method to stimulate retinal M cells, creating a new color, "olo," beyond human vision's natural limits.

Majmudar encourages young surgeons to seek hands-on experience early and often, stressing the importance of real-world practice beyond the classroom.

Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.

Explore innovative glaucoma treatments and technologies, including AI, home monitoring, and new surgical options, to enhance patient care.

Discover groundbreaking advancements in eye care at ASCRS 2025, featuring innovative technologies and research from leading ophthalmology companies.

VivaVision Biotech reveals promising phase 2 trial results for VVN461, a new treatment for Non-Infectious Anterior Uveitis, showcasing safety and efficacy.

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope for innovative retinal therapies.

Canadian investigators urged quick neuro-ophthalmologic referrals to limit the progress of life- and vision-threatening conditions.

From revised patient flow to smarter tech adoption, ophthalmologists share which changes from 2020 have become cornerstones of modern care—and how they’re preparing for the next big disruption

Ophthalmologists reflect on the transformative impact of COVID-19, highlighting adaptations in patient care, safety protocols, and the rise of telemedicine.

ENTOD Pharmaceuticals launches Myatro XL, a 0.05% atropine eye drop, to effectively slow myopia progression in children, available by prescription in 2025.

Bausch + Lomb addresses recent IOL recall, ensuring safety with enhanced protocols and returning enVista lenses to market after thorough investigation.

Industry leaders discuss the impact of rising tariffs on vision care costs, advocating for policy changes to ensure affordable access to essential eyewear.

This population requires careful attention from diagnosis through the entire postoperative process.

Five years after the COVID-19 pandemic shutdown reshaped how the world gathers, here's how some of ophthalmology’s leading associations are still applying lessons forged in crisis